Drugs / OMTX705
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07377045 | Oct 2025 → Mar 2029 expected | pancreatic ductal adenocarcinoma | Oncomatryx Biopharma S.L. | Recruiting | No outcome recorded |
| Phase 1 | NCT05547321 | Oct 2022 → Dec 2027 expected | — | Oncomatryx Biopharma S.L. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMTX705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05547321 ↗ |
| Modality | Other / unclassified | “OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate” NCT05547321 ↗ |
| Route | Intravenous | “OMTX705 administered IV at 2.0, 4.0 or 7.5 mg/kg on days 1 and 8 every 21-days cycle” NCT07377045 ↗ |